in our plan for 2026, we will continue our investments in AI and technologies and other operational processes and sales investments as John has mentioned.

Aug 7, 2026 / receipt

there's a lot of integration work, some technology investments that we're making, ensuring everyone's on consistent platforms and systems,

Aug 7, 2026 / receipt

we execute against the 2026 set of process, technology, and automation work to drive ongoing efficiency improvements.

Aug 7, 2026 / receipt

You know, we have a margin that's higher than that. And our goals will be to drive to our margin over time. And I think we will look to see how quickly we can do that. I would agree. There's a lot of integration work, some technology investments that we're making, ensuring everyone's on consistent platforms and systems, a number of travel initiatives and other things. So we're really excited about that asset and what that will bring. And again, as John mentioned, we are very excited about moving that towards our overall profile.

Aug 7, 2026 / receipt / John, CEO | earnings call 2026-08-07 | transcript f0e46c5f-db88-43cd-bcba-d5d4ebdbc4e8 | chars 35458-35992 | segment 36

I would agree. There's a lot of integration work, some technology investments that we're making, ensuring everyone's on consistent platforms and systems, a number of travel initiatives and other things.

Feb 27, 2026 / receipt, needs a key / Jen, CFO | earnings call 2026-02-27 | transcript 1fb726cb-cba6-4be4-bd18-59f266c2786a | chars 35883-36085 | segment 36

The unaudited pro forma financial information is not necessarily indicative of either future results of operations or results of operations that might have been achieved had the acquisition been consummated as of January 1, 2025 and does not reflect any operating efficiencies and cost savings that may be realized from the integration of the acquisition.

filing / Jul 31, 2026 / receipt

Since 2019, we built upon supportive care services to patients, as we have meaningfully expanded our footprint of highly clinical and expert services to home health, rehabilitation, and hospice patients to address a large national healthcare need and more completely and better serve Senior and Specialty patients in the home as evidenced by continued census growth within the Provider Services segment.

filing / Jul 31, 2026 / receipt

We have a proven ability to augment growth of existing operations by expanding our presence and opening new locations - in both of our reportable segments, Pharmacy Solutions and Provider Services - across geographies with consistent ramp-up in performance after site opening.

filing / Jul 31, 2026 / receipt

(3) Represents costs associated with restructuring-related activities, including closure, and related license impairment, and severance expenses associated with certain enterprise-wide or significant business line cost-savings measures.

filing / Jul 31, 2026 / receipt

The unaudited pro forma financial information is not necessarily indicative of either future results of operations or results of operations that might have been achieved had the acquisition been consummated as of January 1, 2025 and does not reflect any operating efficiencies and cost savings that may be realized from the integration of the acquisition.

filing / May 1, 2026 / receipt

Since 2019, we built upon supportive care services to patients, as we have meaningfully expanded our footprint of highly clinical and expert services to home health, rehabilitation, and hospice patients to address a large national healthcare need and more completely and better serve Senior and Specialty patients in the home as evidenced by continued census growth within the Provider Services segment.

filing / May 1, 2026 / receipt

We have a proven ability to augment growth of existing operations by expanding our presence and opening new locations - in both of our reportable segments, Pharmacy Solutions and Provider Services - across geographies with consistent ramp-up in performance after site opening.

filing / May 1, 2026 / receipt

(3) Represents costs associated with restructuring-related activities, including closure, and related license impairment, and severance expenses associated with certain enterprise-wide or significant business line cost-savings measures.

filing / May 1, 2026 / receipt

and our decisions to exit specific uneconomic customers. | The company is actively pruning unprofitable customers, indicating a focus on efficiency that could be supported by analytics or customer pro

company_statement / Aug 7, 2026 / receipt

Home and community pharmacy revenue declined year over year due to the divestitures associated with a customer that declared bankruptcy | A major customer bankruptcy has negatively impacted a key reve

company_statement / Aug 7, 2026 / receipt

Included in total adjusted EBIDA is expected contribution from the Amedis and LHG acquisition of 30 million. | The integration of the Amedisys and LHG acquisitions creates a need for system consolidat

company_statement / Aug 7, 2026 / receipt

there's a lot of integration work, some technology investments that we're making, ensuring everyone's on consistent platforms and systems, | The company is actively spending on technology to integrate

company_statement / Aug 7, 2026 / receipt